Relmada hires executive with U.S. bladder cancer gene therapy experience
Relmada Therapeutics (Nasdaq: RLMD) has appointed Bipin Dalmia, PhD, MBA, as its Chief Business Officer. Dalmia brings nearly 30 years of biopharmaceutical leadership, including experience leading the Uro-Oncology Franchise and the U.S. launch of ADSTILADRIN, the first FDA-approved intravesical gene therapy for BCG-unresponsive non-muscle …